<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR1800015640</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2018-04-12</date_registration>
      <primary_sponsor>Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine</primary_sponsor>
      <public_title>A study for Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) Regimen followed by ASCT in the treatment of advanced-stage Extranodal NK/T cell lymphoma</public_title>
      <acronym />
      <scientific_title>A study for Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) Regimen followed by ASCT in the treatment of advanced-stage Extranodal NK/T cell lymphoma</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-04-01</date_enrolment>
      <type_enrolment />
      <target_size>Case series:37;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=26617</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>Post-market</phase>
      <hc_freetext>Nk/T cell lymphoma</hc_freetext>
      <i_freetext>Case series:Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) Regimen followed by ASCT;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Zhu Qi</firstname>
        <middlename />
        <lastname />
        <address>639 Zhizaiju Road, Shanghai, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13764188348</telephone>
        <email>zhuqi70@hotmail.com</email>
        <affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Yao yiyun</firstname>
        <middlename />
        <lastname />
        <address>639 Zhizaiju Road, Shanghai, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13818327362</telephone>
        <email>wdx0707@sina.com</email>
        <affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. diagnosed NK/T cell lymphoma  with the pathologically and immunohistochemically confirmed by tumor  tissue;
2. intermediate or high subtype by PINKE risk-factor model with at least one measurable focus;
3. aged &gt;= 16 years;
4. ECOG performance status of &lt;3 with anticipated survival exceeding 3 months;
5. lab tests suitable for chemotherapy.</inclusion_criteria>
      <agemin>16</agemin>
      <agemax>75</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. relapsed or progressed patients treated by Aspargase-contained chemotherapies in recent 6 months;
2. concurrent with HCV or HIV infection;
3. combination with pancreatitis;
4. concurrent with server infection needing ICU care;
5. with serious complications, such as fulminant DIC;
6. important organ failure;
7. pregnant or lactation period;
8. psychonosema;
9. allergy to the drug ofchemotherapy;
10. with secondary tumor need to under operation or chemotherapy in 6 months ahead;
11. in other correlated clinical trial.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Overall survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>progress free survival;response rate;toxicity evaluation;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Project of Clinical Researchï¼Œ Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-03-13</approval_date>
        <contact_name>Zheng Hong</contact_name>
        <contact_address>639 Zhizaiju Road, Shanghai, China</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>